BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

143 related articles for article (PubMed ID: 15961547)

  • 1. Maternal serum invasive trophoblast antigen and first-trimester Down syndrome screening.
    Palomaki GE; Knight GJ; Neveux LM; Pandian R; Haddow JE
    Clin Chem; 2005 Aug; 51(8):1499-504. PubMed ID: 15961547
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Maternal serum invasive trophoblast antigen (hyperglycosylated hCG) as a screening marker for Down syndrome during the second trimester.
    Palomaki GE; Neveux LM; Knight GJ; Haddow JE; Pandian R
    Clin Chem; 2004 Oct; 50(10):1804-8. PubMed ID: 15319323
    [TBL] [Abstract][Full Text] [Related]  

  • 3. A screening program for trisomy 21 at 10-14 weeks using fetal nuchal translucency, maternal serum free beta-human chorionic gonadotropin and pregnancy-associated plasma protein-A.
    Spencer K; Souter V; Tul N; Snijders R; Nicolaides KH
    Ultrasound Obstet Gynecol; 1999 Apr; 13(4):231-7. PubMed ID: 10341399
    [TBL] [Abstract][Full Text] [Related]  

  • 4. ADAM 12 as a first-trimester maternal serum marker in screening for Down syndrome.
    Laigaard J; Spencer K; Christiansen M; Cowans NJ; Larsen SO; Pedersen BN; Wewer UM
    Prenat Diagn; 2006 Oct; 26(10):973-9. PubMed ID: 16892462
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Invasive trophoblast antigen (hyperglycosylated human chorionic gonadotropin) in second-trimester maternal urine as a marker for down syndrome: preliminary results of an observational study on fresh samples.
    Palomaki GE; Knight GJ; Roberson MM; Cunningham GC; Lee JE; Strom CM; Pandian R
    Clin Chem; 2004 Jan; 50(1):182-9. PubMed ID: 14709646
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Maternal serum hyperglycosylated human chorionic gonadotrophin (HhCG) in the first trimester of pregnancies affected by Down syndrome, using a sialic acid-specific lectin immunoassay.
    Spencer K; Talbot JA; Abushoufa RA
    Prenat Diagn; 2002 Aug; 22(8):656-62. PubMed ID: 12210572
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Comparison of serum markers in first-trimester down syndrome screening.
    Canick JA; Lambert-Messerlian GM; Palomaki GE; Neveux LM; Malone FD; Ball RH; Nyberg DA; Comstock CH; Bukowski R; Saade GR; Berkowitz RL; Dar P; Dugoff L; Craigo SD; Timor-Tritsch IE; Carr SR; Wolfe HM; D'Alton ME;
    Obstet Gynecol; 2006 Nov; 108(5):1192-9. PubMed ID: 17077242
    [TBL] [Abstract][Full Text] [Related]  

  • 8. First-trimester combined screening for trisomy 21 at 7-14 weeks' gestation.
    Wright D; Spencer K; Kagan K K; Tørring N; Petersen OB; Christou A; Kallikas J; Nicolaides KH
    Ultrasound Obstet Gynecol; 2010 Oct; 36(4):404-11. PubMed ID: 20658511
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Screening for trisomy 21 by maternal age, fetal nuchal translucency thickness, free beta-human chorionic gonadotropin and pregnancy-associated plasma protein-A.
    Kagan KO; Wright D; Baker A; Sahota D; Nicolaides KH
    Ultrasound Obstet Gynecol; 2008 Jun; 31(6):618-24. PubMed ID: 18461550
    [TBL] [Abstract][Full Text] [Related]  

  • 10. First-trimester combined screening for trisomy 21 with different combinations of placental growth factor, free β-human chorionic gonadotropin and pregnancy-associated plasma protein-A.
    Kagan KO; Hoopmann M; Abele H; Alkier R; Lüthgens K
    Ultrasound Obstet Gynecol; 2012 Nov; 40(5):530-5. PubMed ID: 22611005
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Practical strategies in contingent sequential screening for Down syndrome.
    Benn P; Wright D; Cuckle H
    Prenat Diagn; 2005 Aug; 25(8):645-52. PubMed ID: 16049988
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Impact of bias in serum free beta-human chorionic gonadotropin and pregnancy-associated plasma protein-A multiples of the median levels on first-trimester screening for trisomy 21.
    Wright D; Abele H; Baker A; Kagan KO
    Ultrasound Obstet Gynecol; 2011 Sep; 38(3):309-13. PubMed ID: 21400623
    [TBL] [Abstract][Full Text] [Related]  

  • 13. First trimester maternal serum screening for Down's syndrome: an evaluation of the DPC Immulite 2000 free beta-hCG and pregnancy-associated plasma protein-A assays.
    Spencer K
    Ann Clin Biochem; 2005 Jan; 42(Pt 1):30-40. PubMed ID: 15802030
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The impact of correcting for smoking status when screening for chromosomal anomalies using maternal serum biochemistry and fetal nuchal translucency thickness in the first trimester of pregnancy.
    Spencer K; Bindra R; Cacho AM; Nicolaides KH
    Prenat Diagn; 2004 Mar; 24(3):169-73. PubMed ID: 15057947
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Modeling Down syndrome screening performance using first-trimester serum markers.
    Koster MP; Wortelboer EJ; Stoutenbeek P; Visser GH; Schielen PC
    Ultrasound Obstet Gynecol; 2011 Aug; 38(2):134-9. PubMed ID: 21800388
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Integrated ultrasound and biochemical screening for trisomy 21 using fetal nuchal translucency, absent fetal nasal bone, free beta-hCG and PAPP-A at 11 to 14 weeks.
    Cicero S; Bindra R; Rembouskos G; Spencer K; Nicolaides KH
    Prenat Diagn; 2003 Apr; 23(4):306-10. PubMed ID: 12673635
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Screening for trisomy 21 by fetal tricuspid regurgitation, nuchal translucency and maternal serum free beta-hCG and PAPP-A at 11 + 0 to 13 + 6 weeks.
    Falcon O; Auer M; Gerovassili A; Spencer K; Nicolaides KH
    Ultrasound Obstet Gynecol; 2006 Feb; 27(2):151-5. PubMed ID: 16388509
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Combined measurement of fetal nuchal translucency, maternal serum free beta-hCG, and pregnancy-associated plasma protein A for first-trimester Down's syndrome screening.
    Tsai MS; Huang YY; Hwa KY; Cheng CC; Lee FK
    J Formos Med Assoc; 2001 May; 100(5):319-25. PubMed ID: 11432311
    [TBL] [Abstract][Full Text] [Related]  

  • 19. First-trimester combined ultrasound and biochemical screening for Down syndrome in routine clinical practice.
    Stenhouse EJ; Crossley JA; Aitken DA; Brogan K; Cameron AD; Connor JM
    Prenat Diagn; 2004 Oct; 24(10):774-80. PubMed ID: 15503268
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Maternal serum biochemistry at 11-13(+6) weeks in relation to the presence or absence of the fetal nasal bone on ultrasonography in chromosomally abnormal fetuses: an updated analysis of integrated ultrasound and biochemical screening.
    Cicero S; Spencer K; Avgidou K; Faiola S; Nicolaides KH
    Prenat Diagn; 2005 Nov; 25(11):977-83. PubMed ID: 16245371
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.